Modeling the impact of antiviral for treatment on influenza attack rate in households

Influenza is a respiratory disease that causes epidemics, leading to an estimated 290,000-650,000 deaths each year and many more hospitalizations. Once someone is infected, the best way to reduce the severity of symptoms and prevent serious complications is to use antiviral medications. These antivirals not only help with symptoms but can also reduce the spread of the virus by limiting the chances of others becoming infected if the treatment is started soon after symptoms appear.

In this study, we will use data from a clinical trial (the Centerstone study) to improve models that predict how influenza spreads. Specifically, we will estimate key factors that show how likely an infected person is to pass the virus to others. This study is unique because it measured both the viral load (the amount of virus in a person's system) and the rate at which household members get infected. This will be the first time we estimate how well antiviral treatment affects the spread of influenza from treated individuals, adding valuable knowledge to the existing literature.

Understanding how antiviral treatment influences the spread of influenza is crucial for creating more accurate models that help policymakers make better decisions about antiviral treatment distribution. By combining this new data with information from other clinical trials, we will improve the predictions of how antivirals can be used to control the spread of the virus in larger populations. This, in turn, will help improve public health strategies for treating and preventing influenza.

We will use the data from this trial to compare different models that represent how viral load influences the risk of spreading the infection. These models will be tested against actual infection rates observed in the trial to find the most accurate method for predicting transmission.